Healthcare & Pharmaceuticals
🟢 SERP-Grounded (Light Telemetry)
Cognate BioServices
Programmatic AI Search & Model Visibility Audit
Share of Model (SOM)The percentage of time frontier AI models (ChatGPT, Claude, Gemini) recommend this brand for high-intent category queries.
8.0%
+1.5% 30-Day MomentumThe rolling 30-day change in algorithmic Share of Model. Positive momentum indicates increasing AI mindshare.
🧠 Neural Valency:VulnerableThe contextual sentiment of the AI's recommendation. 'Dominant' implies strong conviction, while 'Vulnerable' implies the model heavily conditions its recommendation.
Algorithmic Threat Detection
Primary Competitor Threat
Lonza
Competitor Displacement Rate
45.0%
Competitors are displacing Cognate BioServices in 45.0% of high-intent buyer queries.The frequency at which AI models actively suggest a competitor as a superior alternative to this brand.
Algorithmic Rationale: Smaller market share and less brand recognition in the competitive cell and gene therapy CDMO space.
Missing AI Citations:High-authority domains (e.g., Reddit, G2) that models cite to justify recommending competitors, where this brand currently lacks presence.
[cellandgene.com][outsourcedpharma.com][biopharma-reporter.com]⚠️ Identified Vulnerability:Brand Recognition
Primary Threat Identified:Lonza
Target Persona:Biotech executives seeking CDMO partners
🚨 Threat Velocity:8/10An algorithmic urgency score (1-10) indicating how rapidly competitors are capturing this brand's historical AI search share.
Unlock Full Threat Report (30 Free Credits)